Abstract 1211P
Background
In IMpower010 (NCT02486718), ctDNA+ status after surgery (post-op) was associated with poor prognosis; atezo was beneficial vs BSC regardless of post-op ctDNA status (Zhou ESMO-IO 2021). Post-chemo, ctDNA clearance (ctDNA−; 62% of post-op ctDNA+ pts) was associated with improved DFS; ctDNA levels were maintained in ctDNA+ pts, and conversion to ctDNA+ was delayed with atezo in ctDNA− pts (Felip ESMO-IO 2022). At final DFS and 2nd IA of overall survival (OS) with ≥5y of follow up, DFS benefit with atezo continued to translate into a positive OS trend vs BSC in PD-L1 tumour cell (TC) ≥1% and TC ≥50% stage II-IIIA pts. We report updated DFS and OS by ctDNA and PD-L1 status.
Methods
Pts with resected (R0) stage IB-IIIA NSCLC and ECOG PS 0-1 who had 1-4 cycles of chemo post-op were randomised 1:1 to atezo 1200 mg Q3W (16 cycles) or BSC. We analysed DFS and OS by ctDNA and PD-L1 (by SP263 IHC) status in post-op ctDNA evaluable pts with stage II-IIIA NSCLC. Plasma samples for ctDNA testing were collected post-op before chemo and post-chemo at Cycle 1 (post-op ctDNA+ pts only) and analysed per the Natera Signatera RUO assay.
Results
Of 1005 randomised pts, 600 were ctDNA evaluable. At data cutoff (26 Jan 2024), 112 of 534 post-op pts (21%) were ctDNA+. DFS and OS outcomes by ctDNA and PD-L1 status are in the table. Median DFS was longer in pts with ctDNA‒ vs ctDNA+ post-op and post-chemo. Longer DFS was seen with atezo vs BSC regardless of ctDNA status. In the post-op PD-L1 TC ≥1% population, a trend toward OS benefit was seen in ctDNA+ and ctDNA‒ pts.
Conclusions
Post-op and post-chemo ctDNA positivity was a negative prognostic factor for DFS after 5y of follow up. Regardless of ctDNA status, DFS and OS benefit with atezo vs BSC was seen in pts with stage II-IIIA PD-L1 TC ≥1% NSCLC. Chemo-mediated ctDNA– was associated with longer DFS. DFS was longer with atezo vs BSC regardless of post-chemo ctDNA status. Table: 1211P
DFS and OS by ctDNA and PD-L1 status in stage II-IIIA ctDNA-evaluable pts
| Group | ctDNA status | PD-L1 status | Median DFS, mo | HR (95%CI) | ||
| Atezo | BSC | |||||
| Post-op | ‒ | All | n=218NE | n=20460.6 | 0.74 (0.56, 0.98) | |
| TC ≥1% | n=124NE | n=9852.6 | 0.60 (0.40, 0.89) | |||
TC Clinical trial identificationNCT02486718. Editorial acknowledgementMedical writing assistance for this manuscript was provided by Bena Lim, PhD, CMPP, of Nucleus Global, an Inizio Company, and funded by F. Hoffmann-La Roche Ltd. Legal entity responsible for the studyF. Hoffmann-La Roche Ltd. FundingF. Hoffmann-La Roche, Ltd. DisclosureH. Wakelee: Financial Interests, Personal, Advisory Board, Served on a DSMC, completed November 2022: Mirati; Financial Interests, Personal, Invited Speaker, Develop and present a series of lectures: Fishawack Facilitate LTD; Financial Interests, Personal, Invited Speaker, Series of CME lectures: Medscape, Research to Practice; Financial Interests, Personal, Other, Discussion of new data at conferences: Curio Science; Financial Interests, Personal, Invited Speaker, Series of lectures/webinars for PER/OncLive: MJH Holdings; Financial Interests, Personal, Invited Speaker, CME lecture: Axis Medical Education, ParadigmMC, Prova Education; Financial Interests, Personal, Advisory Board: IOBiotech; Financial Interests, Personal, Invited Speaker, Facilitated speaking at several virtual conferences: Shanghai Bird Translation and Consulting; Financial Interests, Personal, Invited Speaker, Invited speaker at virtual symposium: China International Medical Foundation; Financial Interests, Personal, Invited Speaker, Invited to speak and moderate at JLCS meetings: Japanese Lung Cancer Society; Financial Interests, Personal, Invited Speaker, Presented at several CME conferences: Medical Educator Consortium; Financial Interests, Personal, Invited Speaker, Facilitated discussion of recent data: IDEOlogy Health; Financial Interests, Personal, Invited Speaker, Invited CME lecture: Vindico Medical Education; Financial Interests, Personal, Invited Speaker, Invited speaker at symposium: Taiwan Association for the Study of Lung Cancer (TASLC); Financial Interests, Personal, Royalties, I receive royalties for a chapter I wrote for UpToDate: UpToDate; Financial Interests, Institutional, Local PI, Clinical Trial Conduct: AstraZeneca/MedImmune, BMS, Seagen, Xcovery; Financial Interests, Institutional, Steering Committee Member, Clinical Trial Conduct: Genentech/Roche, Merck; Financial Interests, Institutional, Local PI, clinical trial conduct: Helsinn; Financial Interests, Institutional, Coordinating PI, IIT for single site: Bayer; Financial Interests, Personal, Steering Committee Member, uncompensated steering committee member: Merck, AstraZeneca, Genentech/Roche; Financial Interests, Personal, Other, uncompensated advisory board participation: BMS; Non-Financial Interests, Officer, Past President: International Association for the Study of Lung Cancer (IASLC); Non-Financial Interests, Leadership Role, Executive Committee: ECOG-ACRIN. M. Reck: Financial Interests, Personal, Invited Speaker: Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Lilly, MSD, Merck, Novartis, Regeneron, Roche, Sanofi, GSK, Pfizer; Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, BMS, Biontech, Boehringer Ingelheim, Daiichi Sankyo, Gilead, MSD, Mirati, Pfizer, Regeneron, Roche, Sanofi, GSK, Lilly; Financial Interests, Personal, Other, Member of DMSB: Daiichi Sankyo; Financial Interests, Personal, Coordinating PI: AstraZeneca; Financial Interests, Institutional, Steering Committee Member: Amgen, Boehringer Ingelheim, Beigene, Daiichi Sankyo, GSK, BMS, Lilly, MSD, Regeneron, Roche; Financial Interests, Institutional, Local PI: Pfizer Seagen. E. Felip: Financial Interests, Personal, Advisory Board: AbbVie, Amgen, AstraZeneca, Bayer, Beigene, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, Gilead, GSK, Janssen, Merck Serono, Merck Sharp & Dohme, Novartis, Peptomyc, Regeneron, Sanofi, Takeda, Turning Point, Pfizer; Financial Interests, Personal, Invited Speaker: Amgen, Daiichi Sankyo, Genentech, Janssen, Medical Trends, Medscape, Merck Serono, PeerVoice, Pfizer, Sanofi, Takeda, Touch Oncology, AstraZeneca, Bristol Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, Merck Sharp & Dohme; Financial Interests, Personal, Member of Board of Directors, Independent member: Grifols; Financial Interests, Institutional, Local PI, Clinical Trial: AstraZeneca AB, AbbVie, Amgen, Bayer Consumer Care AG, Beigene, Boehringer Ingelheim GmbH, Bristol Myers Squibb International Corporation, Daiichi Sankyo Inc., Exelixis Inc., F. Hoffmann-La Roche Ltd., Genentech Inc., GSK Research and Development Limited, Janssen Cilag International NV, Merck Sharp & Dohme Corp, Merck KGAA, Mirati Therapeutics Inc, Novartis Pharmaceutica SA, Pfizer, Takeda Pharmaceuticals International; Non-Financial Interests, Leadership Role, President (2021-2023): SEOM (Sociedad Espanola de Oncologia Medica); Non-Financial Interests, Member, Member of Scientific Committee: ETOP (European Thoracic Oncology Platform); Non-Financial Interests, Member, Member of the Scientific Advisory Committee: CAC Hospital Universitari Parc Taulí. N.K. Altorki: Financial Interests, Institutional, Research Grant, clinical trial: AstraZeneca. E. Vallieres: Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, Merck, Oncocyte. S. Oizumi: Financial Interests, Personal, Other, Honorarium: AstraZeneca, Chugai Pharmaceutical, MSD. H. Tanaka: Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai pharmaceutical, Boehringer Ingelheim, Eli Lilly, MSD, Ono pharmaceutical, Merck, Novartis, Takeda pharmaceutical, Pfizer, Daiichi Sankyo pharmaceutical, Taiho pharmaceutical, Bristol Myers Squibb, EISAI, Hisamitsu pharmaceutical, Nippon Kayaku; Financial Interests, Institutional, Local PI: Chugai pharmaceutical, Merck, AstraZeneca, MSD, Eli Lilly, Ono pharmaceutical, Bristol Myers Squibb, Merck, Takeda pharmaceutical, Taiho pharmaceutical, Pfizer, Daiichi Sankyo pharmaceutical, AbbVie, Amgen, Janssen pharmaceutical. S. McCune: Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb, Genentech; Financial Interests, Institutional, Local PI, Funding for Clinical Trial: Genentech. E. Bennett: Financial Interests, Personal, Full or part-time Employment: Genentech, Roche; Financial Interests, Personal, Stocks or ownership: Genentech, Roche. B.J. Gitlitz: Financial Interests, Personal, Full or part-time Employment: Genentech, Roche; Financial Interests, Personal, Stocks or ownership: Genentech, Roche. V.A. McNally: Financial Interests, Personal, Full or part-time Employment: Genentech, Roche; Financial Interests, Personal, Stocks or ownership: Genentech, Roche. S. Novello: Financial Interests, Personal, Invited Speaker: AZ, MSD, Eli Lilly, Novartis, Beigene, Amgen, Thermo Fisher; Financial Interests, Personal, Advisory Board: BI, BMS, Pfizer, Takeda, Roche, Sanofi, Amgen, J&J; Financial Interests, Institutional, Coordinating PI, IIT: MSD, BI; Financial Interests, Institutional, Coordinating PI: AZ, AMG, Eli Lilly, Sanofi, J&J, Roche; Non-Financial Interests, Leadership Role, president of this European advocacy: WALCE; Non-Financial Interests, Member: IASLC, AIOM, ASCO. M. Ballinger: Financial Interests, Personal, Full or part-time Employment: Genentech, Roche; Financial Interests, Personal, Stocks or ownership: Genentech, Roche. W. Zou: Financial Interests, Personal, Full or part-time Employment: Genentech, Roche; Financial Interests, Personal, Stocks or ownership: Genentech, Roche. B. Nabet: Financial Interests, Personal, Full or part-time Employment: Genentech; Financial Interests, Personal, Stocks/Shares: Roche. M. Srivastava: Financial Interests, Personal, Full or part-time Employment: Genentech, Roche; Financial Interests, Personal, Stocks or ownership: Genentech, Roche. C. Zhou: Financial Interests, Personal, Advisory role, Consulting fees: Innovent Biologics, Qilu, Hengrui, TopAlliance Biosciences Inc.; Financial Interests, Personal, Other, Payment or honoraria from: Eli Lilly China, Sanofi, Boehringer Ingelheim, Roche, Merck Sharp & Dohme, Qilu, Hengrui, Innovent Biologics, Alice, C-Stone, LUYE Pharma, TopAlliance Biosciences Inc., Amoy Diagnostics, AnHeart. All other authors have declared no conflicts of interest. Resources from the same session1221P - Stereotactic ablative radiotherapy in combination with nivolumab for early stage operable non-small cell lung cancer: A phase II studyPresenter: Gustavo Schvartsman Session: Poster session 04 1222P - Predicting pathological complete response to neoadjuvant chemoimmunotherapy in resected NSCLC with radiomic signaturesPresenter: Mohammadhadi Khorrami Session: Poster session 04 Resources: Abstract 1223P - Sex specific efficacy and safety outcomes in operable stage III non-small cell lung cancer (NSCLC): Pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14Presenter: Lorenz Frehner Session: Poster session 04 1224P - Evaluation of safety and feasibility of adjuvant chemotherapy in elderly patients with primary non-small cell lung cancerPresenter: Alice MOGENET Session: Poster session 04 1225P - Perioperative serplulimab and chemotherapy in patients with resectable squamous non-small cell lung cancer: An open-label, single-arm, phase II trialPresenter: Haiquan Chen Session: Poster session 04 1226P - Predictive value of circulating tumor DNA (ctDNA) before and shortly after curative treatment in early stage non-small cell lung cancer (NSCLC), and exploration of (pre-)analytical factorsPresenter: Michel van den Heuvel Session: Poster session 04 1227P - Update on the analysis of operability parameter changes in neoadjuvant treatment with chemotherapy and anti-PD-1/PD-L1Presenter: Maria Sereno Session: Poster session 04 1228P - Association between air pollution and frequency of driver mutation among a Hispanic population with lung cancerPresenter: Mateo Tamayo Session: Poster session 04 Resources: Abstract 1229P - Precision patient selection for postoperative therapy in resectable NSCLC: A comprehensive postoperative-risk model incorporating genetic and histological featuresPresenter: Yuanzi Ye Session: Poster session 04 1230P - Association between early endpoints and survival outcomes in neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC): A multi-country retrospective studyPresenter: Mariano Provencio Pulla Session: Poster session 04 This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
| ||||||